The current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies. Supplementary Information The online version contains supplementary material available at 10.1186/s12985-021-01737-3.
【저자키워드】 SARS-CoV-2 variant, Inactivated vaccine, Mutant RBD vaccine, Sequential immunization, Broadly neutralizing antibody, 【초록키워드】 public health, SARS-CoV-2, Vaccine, immunogenicity, Inactivated Vaccines, Neutralizing antibodies, COVID-19 pandemic, variant, Delta, variants, SARS-CoV-2 variants, Inactivated vaccine, mice, RBD, Alpha, Beta, mutant, booster dose, Neutralizing antibody response, Heterologous, NAb, booster vaccines, booster vaccination, Booster vaccine, dose, Iota, supplementary material, These data, NAbs, GMTs, wild-type, A.23.1, immunized mice, tested, caused, significantly, addition, evaluated, induce, GMT, 【제목키워드】 Vaccine, neutralization, variant, immunization, SARS-CoV-2 RBD, induce,